CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis
Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial
Fernando Alfonso, MD*,*,
Maria-José Pérez-Vizcayno, MD*,
Rosana Hernandez, MD*,
Armando Bethencourt, MD ,
Vicens Martí, MD ,
Jose R. López-Mínguez, MD ,
Juan Angel, MD||,
Ramón Mantilla, MD¶,
Cesar Morís, MD#,
Angel Cequier, MD**,
Manel Sabaté, MD*,
Javier Escaned, MD*,
Raúl Moreno, MD*,
Camino Bañuelos, MD*,
Alfonso Suárez, MD*,
Carlos Macaya, MD* for the RIBS-II Investigators
* Clinico San Carlos University Hospital, Madrid, Spain
Son Dureta University Hospital, Palma de Mallorca, Spain
San Pablo University Hospital, Barcelona, Spain
Infanta Cristina University Hospital, Badajoz, Spain
|| Valle de Hebrón University Hospital, Barcelona, Spain
¶ Meixoeiro University Hospital, Vigo, Spain
# Central Asturias University Hospital, Oviedo, Spain
** Bellvitge University Hospital, Barcelona, Spain
Manuscript received August 21, 2005;
revised manuscript received October 14, 2005,
accepted October 25, 2005.
* Reprint requests and correspondence: Dr. Fernando Alfonso, Cardiología Intervencionista, Instituto Cardiovascular, Hospital Universitario "San Carlos," Ciudad Universitaria, Plaza de Cristo Rey, Madrid 28040, Spain. (Email: falf{at}hotmail.com).
OBJECTIVES: We sought to assess the effectiveness of sirolimus-eluting stents (SES) in patients with in-stent restenosis (ISR).
BACKGROUND: Treatment of patients with ISR remains a challenge.
METHODS: The Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) study is a multicenter randomized trial conducted in 150 patients with ISR (76 allocated to SES and 74 to balloon angioplasty [BA]). The primary end point was recurrent restenosis rate at nine months. Secondary end points included prespecified subgroup analysis, lumen volume on intravascular ultrasound (IVUS), and a composite of major clinical events at one year.
RESULTS: Angiographic success was obtained in all patients. At 9-month angiographic follow-up (96% of eligible patients) minimal lumen diameter was larger (2.52 mm [interquartile range (IQR) 2.09 to 2.81] vs. 1.54 mm [IQR 0.91 to 2.05]; p < 0.001) and recurrent restenosis rate was lower (11% vs. 39%; p < 0.001) in the SES group. Prespecified subgroup analyses were consistent with the main outcome measure. Lumen volume on IVUS at 9 months was also larger (279 mm3 [IQR 227 to 300] vs. 197 mm3 [IQR 177 to 230]; p < 0.001) in the SES group. At one-year clinical follow-up (100% of patients), the event-free survival (freedom from death, myocardial infarction, and target vessel revascularization) was significantly improved in the SES group (88% vs. 69%; p < 0.004) as the result of a lower requirement for target vessel revascularization (11% vs. 30%; p < 0.003).
CONCLUSIONS: In patients with ISR, the use of SES provides superior long-term clinical, angiographic, and IVUS outcome than BA treatment.
|
Abbreviations and Acronyms
| | BA = balloon angioplasty | | IQR = interquartile range | | ISR = in-stent restenosis | | IVUS = intravascular ultrasound | | PCI = percutaneous coronary interventions | | RIBS-II = Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting study | | SES = sirolimus-eluting stents |
|
Related Article
-
Treatment of Stent Restenosis: Moving Beyond Momentum
- Harold L. Dauerman
J. Am. Coll. Cardiol. 2006 47: 2161-2163.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, A. Iniguez, C. Moris, A. Cequier, et al.
Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1621 - 1627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Habara, K Mitsudo, T Goto, K Kadota, S Fujii, H Yamamoto, H Kato, S Takenaka, Y Fuku, S Hosogi, et al.
The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis
Heart,
September 1, 2008;
94(9):
1162 - 1165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri
Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1844 - 1853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Grines
Off-label use of drug-eluting stents putting it in perspective.
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
615 - 617.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dibra, A. Kastrati, F. Alfonso, M. Seyfarth, M.-J. Perez-Vizcayno, J. Mehilli, and A. Schomig
Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials
J. Am. Coll. Cardiol.,
February 6, 2007;
49(5):
616 - 623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Alfonso, H. Jneid, A. O. Maree, I. F. Palacios, M. Valgimigli, G. Percoco, L. Bolognese, C. Spaulding, P. Henry, E. Teiger, et al.
Drug-eluting stents in primary PCI.
N. Engl. J. Med.,
December 7, 2006;
355(23):
2483 - 2484.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. Dauerman
Treatment of Stent Restenosis: Moving Beyond Momentum
J. Am. Coll. Cardiol.,
June 6, 2006;
47(11):
2161 - 2163.
[Full Text]
[PDF]
|
 |
|
|